| Literature DB >> 23316220 |
Jens Boesger1, Volker Wagner, Wolfram Weisheit, Maria Mittag.
Abstract
The green biflagellate alga Chlamydomonas reinhardtii serves as model for studying structural and functional features of flagella. The axoneme of C. reinhardtii anchors a network of kinases and phosphatases that control motility. One of them, Casein Kinase 1 (CK1), is known to phosphorylate the Inner Dynein Arm I1 Intermediate Chain 138 (IC138), thereby regulating motility. CK1 is also involved in regulating the circadian rhythm of phototaxis and is relevant for the formation of flagella. By a comparative phosphoproteome approach, we determined phosphoproteins in the flagellum that are targets of CK1. Thereby, we applied the specific CK1 inhibitor CKI-7 that causes significant changes in the flagellum phosphoproteome and reduces the swimming velocity of the cells. In the CKI-7-treated cells, 14 phosphoproteins were missing compared to the phosphoproteome of untreated cells, including IC138, and four additional phosphoproteins had a reduced number of phosphorylation sites. Notably, inhibition of CK1 causes also novel phosphorylation events, indicating that it is part of a kinase network. Among them, Glycogen Synthase Kinase 3 is of special interest, because it is involved in the phosphorylation of key clock components in flies and mammals and in parallel plays an important role in the regulation of assembly in the flagellum.Entities:
Year: 2012 PMID: 23316220 PMCID: PMC3536430 DOI: 10.1155/2012/581460
Source DB: PubMed Journal: Int J Plant Genomics ISSN: 1687-5389
Figure 1Enrichment of CK1 in flagella and the influence of CK1 inhibition on the phosphorylation status of flagellum proteins and swimming velocity of C. reinhardtii cells. (a) Cells were grown in TAP in a 12 h light-12 h dark cycle and then released to dim light (LL) according to Section 2. Cells were harvested at LL29 and flagella were isolated and a whole cell crude extract (CE), a flagellar extract (FL), and an extract from cell bodies lacking flagella (CB) were prepared. 25 μg proteins per fraction were separated by SDS-PAGE and analyzed by immunoblotting with anti-CK1 antibodies according to Section 2. (b) For quantifications, the amount of CK1 detected in the whole cell crude extract was set to 100%. Quantifications were done with three biological replicates using the ImageMaster 2D Elite Vs.4.01 software (GE Healthcare). (c) Changes in the phosphorylation pattern of flagellum proteins in cells treated with and without CKI-7. Cells were grown as described above (a) in the presence or absence of CKI-7 and harvested at LL29 before isolation of flagella. Proteins from the MMA fraction of the flagellum (25 μg each lane) were separated by 9% SDS-PAGE along with a molecular mass standard and immunoblotted with specific antibodies against phosphoSer according to Section 2. Changes in the phosphorylation status of proteins after CKI-7 treatment are indicated by “+” and “−” signs, respectively. (d) Swimming velocity of 137c cells in the absence (−CKI-7) or presence of CK1 inhibitor (+CKI-7). Cells were grown at 23°C in a LD cycle. Measurements of swimming velocity were done with a hemocytometer and a differential interference contrast microscope with a total magnification of 400 including a personal computer with a video recording system to measure displacement versus time (n = 10). Error bars represent the SEM.
Phosphoproteins identified in 137c [11] whose phosphopeptides or phosphorylation sites are missing in CKI-7-treated cells.
| Flagellar central pair-associated protein; PF6 | |
| Hydin-like protein; HYD3 | |
| Inner dynein arm I1 intermediate chain; IC138 | |
| Intraflagellar transport protein IFT43 | |
| Outer dynein arm docking complex subunit 1a,b; ODA-DC1, ODA3 | |
| Radial spoke protein 17; RSP17 | |
| FAP59c; RecF/RecN/SMC N-terminal domain | |
| FAP116a,d,e; microtubule-binding protein MIP-T3 domain | |
| FAP190a,f; sterile alpha motif | |
| FAP228; callose synthase-like protein; 1,3-beta-glucan synthase component | |
| FAP230; ankyrin repeats; ion transport protein domain | |
| FAP254; putative ankyrin-like protein | |
| FAP288; EF hand | |
| FAP1a,g | |
| FAP93 | |
| FAP147 | |
| FAP184 | |
| FAP263 |
The function of depicted proteins is given as determined by NCBI BLASTp, along with their conserved domains.
aNot all previously identified peptides (listed in Table S1 in [11]) are present in the CKI-7-treated cells.
bVariants of peptide TISGADTPEEVLAYWEGLK with the phosphorylation sites Thr-345, Ser-347, and Thr-351 as well as variants of peptide ILGYTGSDVEEEEPESEEETEEEANKDDGVVDR with the phosphorylation sites Tyr-697 and Ser-709 are missing.
cPredicted functional domains are present only in the Vs3 model.
dVs2 model differs significantly from Vs3 model.
eThe phosphorylation site Ser-255 in peptide SASPGGEDPLNKSGSAAPK is missing.
fVariants of peptide STSSIGGGYSEPVGSDGEGSDAASAKPR with phosphorylation sites on Ser-370, Ser-375 and Ser-379 are missing.
gThe phosphorylation site Ser-55 in peptide SRGSFQEGQAMVR is missing.
Additional phosphopeptides/phosphorylation sites in CKI-7-treated cells of either novel phosphoproteins or phosphoproteins that were already identified in 137c [11].
| Phosphoproteins only present in CKI-7-treated 137c cells | |
|---|---|
| Glycogen synthase kinase 3; GSK3 | |
| Kinesin-like protein; Kinesin motor domain, KIF9-like subgroup | |
| Phosphoglucomutase | |
| Radial spoke protein 11; RSP11; RIIa domain | |
| S-Adenosylmethionine synthetase | |
| FAP139a; TIGR02680 domain | |
| FAP21a | |
| FAP56 | |
| FAP75 | |
| FAP98 | |
| FAP129 | |
| FAP165a | |
| FAP236 | |
| FAP241 | |
| FAP243 (Vs3 FAP183)a | |
|
| |
| Phosphoproteins found in CKI-7-treated cells with additional phosphopeptide(s) in comparison to 137c | |
|
| |
| Outer dynein arm docking complex protein 2; ODA-DC2 | |
| FAP33a,b; ankyrin repeats | |
| FAP154a | |
| FAP217 | |
|
| |
| Phosphoproteins found in CKI-7-treated cells with the same peptide [ | |
|
| |
| FAP39a; plasma membrane calcium transporting ATPase | |
| MAK7a; mitogen activated protein kinase 7 | |
The function of depicted proteins is given as determined by NCBI BLASTp, along with their conserved domains.
aVs2 model differs significantly from Vs3 model.
bPredicted functional domains are present only in the Vs3 model.
Figure 2Analysis of CK1 targets in the flagellum. (a) Diagram of flagellum phosphoproteins in wild-type and CK1-inhibited cells. A cross-section of a flagellum from C. reinhardtii (left panel) and a more detailed view (red rectangle) are shown according to [11]. Structural phosphoproteins in CKI-7-inhibited cells, and such with a reduced number of phosphorylation sites are indicated in yellow color with a red frame. Novel phosphopeptides of structural proteins or additional phosphorylation sites of known phosphopeptides from structural phosphoproteins that were identified in the CKI-7-inhibited proteome are indicated by yellow color with a blue frame. Structural proteins with previously identified phosphopeptides, whose phosphorylation sites were detected again, are indicated in yellow without frame. Abbreviations are: C1 central pair projection (C1P), C2 central pair projection (C2P), PF6 protein (PF6), Hydin (H), Radial Spoke Protein17 (RSP17); Outer Dynein Arm Docking Complex (DC); Inner Dynein Arm Intermedite Chain138 (IC138), Tectin (T) as well as an Intraflagellar Transport Protein43 (IFT43). (b) and (c) Positions of identified phosphopeptides in the predicted domains of RSP11 (b) and GSK3 (c). Identified phosphopeptides are indicted by black boxes. The amino acid positions are mentioned. “p” indicates in vivo phosphorylation sites. RIIa, regulatory subunit of cAMP-Dependent Protein Kinase A; Ser/Thr Kin, Ser/Thr protein kinase catalytic domain. (d) and (e) Hypothetical model of GSK3 de-/activation via reversible phosphorylation triggered by CK1. (d) Regulatory signaling involves an additional kinase. The noninhibited active form of CK1 inactivates another still unknown kinase by phosphorylation. This kinase is needed in its active nonphosphorylated form for activating GSK3. (e) If CK1 is inhibited by CKI-7, the unknown kinase is not phosphorylated and thus active. This active kinase phosphorylates in turn GSK3, which is then activated.